SCHEMBL17294252

SCHEMBL17294252

O=C(O)c1ccncc1C(F)F

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 17/20 0.53
KDM6B O15054 7/20 0.53
KDM4D Q6B0I6 4/20 0.53
KDM4E B2RXH2 3/20 0.53
KDM4A O75164 2/20 0.53
ALDH1A1 P00352 2/20 0.53
MEN1 O00255 1/20 0.53
MAPT P10636 1/20 0.53
THRB P10828 1/20 0.53
KMT2A Q03164 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ASPH Q12797 1/20 0.39
KDM8 Q8N371 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
APP P05067 1/20 0.38
GAA P10253 1/20 0.38
HCAR3 P49019 1/20 0.38
HCAR2 Q8TDS4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29219093 0.85 KDM4C (0.50) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL3932429 0.85 KDM4C (0.48) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL17294374 0.83 KDM4C (0.39) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL16344094 0.83 KDM4C (0.40) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL16094232 0.83 TDP1 (0.50) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL17465921 0.81 KDM4C (0.53) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL28318173 0.78 KDM4C (0.55) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL9307980 0.77 KDM4C (0.56) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL71335 0.74 KDM4C (0.65) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL29416303 0.74 KDM4C (0.65) KDM4CKDM6BKDM4DKDM4EKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2023-10-10 US disclosed
US-20220281850-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2022-09-08 US disclosed
EP-3148975-A1 NOVEL COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2017-04-05 EP disclosed
WO-2015180612-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 KDM4C 1502/4885KDM6B 2166/4885KDM4D 1106/4885
US-20220281850-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 KDM4C 1502/4885KDM6B 2166/4885KDM4D 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.